Anora Ellipta Dosing and Administration
Anora Ellipta (umeclidinium/vilanterol 62.5/25 mcg) is administered as ONE inhalation ONCE daily, at the same time each day. 1, 2
Standard Dosing Regimen
- One puff (inhalation) once daily is the complete dose—this is not "one puff per nostril" as with nasal sprays 1, 2
- The medication should be taken at the same time every day to maintain consistent bronchodilation 1
- Never use more than once in 24 hours—exceeding this frequency provides no additional benefit and increases adverse event risk 1
Administration Technique
- After inhalation, rinse your mouth with water and spit it out (do not swallow) to reduce the risk of oral thrush 1
- The Ellipta device is a dry powder inhaler that delivers a pre-measured dose with each actuation 2
- No priming or shaking is required with the Ellipta device 2
Clinical Context and Indications
Anora Ellipta is indicated for maintenance treatment of COPD only—it combines a long-acting muscarinic antagonist (umeclidinium) with a long-acting beta-agonist (vilanterol) for dual bronchodilation 2. This differs from combination products containing inhaled corticosteroids.
- Anora provides superior bronchodilation compared to either component alone and is more effective than tiotropium monotherapy at improving lung function 2
- It is particularly appropriate for COPD patients who need dual bronchodilation but where inhaled corticosteroid risks outweigh benefits (e.g., recurrent pneumonia, no eosinophilic inflammation) 3
Common Pitfalls to Avoid
- Do not confuse with Breo Ellipta (fluticasone furoate/vilanterol), which contains an inhaled corticosteroid and is dosed similarly but has different indications and risk profiles 4, 1
- This is not a rescue inhaler—patients need a separate short-acting bronchodilator (like albuterol) for acute symptom relief 1, 2
- The most common adverse events are headache and nasopharyngitis, but cardiovascular events are not increased at recommended doses 2